Tech Transfer eNews Blog

Wayne State U licenses out therapeutic for PTSD and other CNS disorders


By Jesse Schwartz
Published: September 4th, 2019

Clinical stage biopharmaceutical company Tonix Pharmaceuticals Holding Corp. has entered into an exclusive license agreement with Wayne State University (WSU) to commercialize a treatment for post-traumatic stress disorder (PTSD) and other central nervous system (CNS) disorders.

Developed by WSU professor Aloke Dutta, the licensed technology is a triple reuptake inhibitor (TRI) known as TNX-1600. It simultaneously inhibits the reuptake of three neurotransmitters — serotonin, norepinephrine and dopamine — that play a key role in many CNS processes. The technology received funding from a National Institutes of Health grant.

“We have developed an innovative triple reuptake inhibitor … based on a unique pyran molecular scaffold to address the current therapeutic needs for PTSD and other neurological disorders,” says Dutta. “Based on our preliminary data, we expect a pharmacological synergy from their potent modulatory effect on the level of monoamine neurotransmitters in the brain, which should facilitate effective treatment of these disorders.”

Seth Lederman, president and CEO of Tonix, comments, “We are excited to expand our pipeline and are looking forward to developing TNX-1600 as a potential treatment for PTSD. We plan to utilize our clinical experience in PTSD to evaluate the therapeutic benefit of TNX-1600.”

Source: Wayne State University

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment